Literature DB >> 26131157

Enhanced sedative efficacy and delayed recovery in propofol anesthesia in a rat model of hepatic cirrhosis.

Xuexin Chen1, Rui Yan1, Zhixia Bai1, Hanxiang Ma1.   

Abstract

PURPOSE: The sedative efficacy of propofol anesthesia is enhanced in patients with hepatic cirrhosis. Establish a rat model to investigate the efficacy of propofol.
METHODS: 100 healthy Sprague-Dawley rats were divided into three groups and administered Phenobarbital sodium, carbon tetrachloride and ethanol solution for 0 (control), 9 (mild cirrhosis, M1), or 12 (severe cirrhosis, M2) weeks to induce hepatic cirrhosis. Propofol was infused via the caudal vein and the ED50 of the sedative effect and the recovery time were assessed according to the loss and recovery of the righting reflex. The effect of propofol on circulating cells and platelets, blood biochemistry and neurotransmitter content of the brain were measured.
RESULTS: Cirrhosis was achieved in 25 of 35 M1 and 27 of 45 M2 rats. The propofol ED50 was significantly lower in M1 and M2 (5.8 ± 1.2 and 4.8 ± 1.1 mg/kg, respectively) than in control rats (6.2 ± 1.1 mg/kg, P < 0.05), and the time to recovery of righting reflex was significantly longer in M1 and M2 (370.0 ± 108.2 s and 501.6 ± 100.1 s, respectively) than in control rats (275.0 ± 90.3 s, P < 0.05). In M1 and M2 rats white and red blood cell and platelet counts were reduced, but ALT and AST activity was increased. In M1 and M2 rats the cerebral content of Gly and GABA increased but Glu and Asp were reduced.
CONCLUSION: The sedative efficacy of propofol anesthesia is enhanced in rats with hepatic cirrhosis, perhaps due to reduced hepatic functional reserve, enhancement of inhibitory neurotransmitters and reduction of excitatory neurotransmitters.

Entities:  

Keywords:  Hepatic cirrhosis; anesthesia recovery period; hepatic function; neurotransmitters; propofol; sedation

Year:  2015        PMID: 26131157      PMCID: PMC4483902     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  24 in total

Review 1.  Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure?

Authors:  E A Jones; A S Basile
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

2.  Modeling liver fibrosis in rodents.

Authors:  Christothea Constandinou; Neil Henderson; John P Iredale
Journal:  Methods Mol Med       Date:  2005

3.  A conserved tyrosine in the beta2 subunit M4 segment is a determinant of gamma-aminobutyric acid type A receptor sensitivity to propofol.

Authors:  James E Richardson; Paul S Garcia; Kate K O'Toole; Jason M C Derry; Shannon V Bell; Andrew Jenkins
Journal:  Anesthesiology       Date:  2007-09       Impact factor: 7.892

4.  Amino acid determination in biological fluids by automated ion-exchange chromatography: performance of Hitachi L-8500A.

Authors:  J Le Boucher; C Charret; C Coudray-Lucas; J Giboudeau; L Cynober
Journal:  Clin Chem       Date:  1997-08       Impact factor: 8.327

5.  Detoxification of ammonia in mouse cortical GABAergic cell cultures increases neuronal oxidative metabolism and reveals an emerging role for release of glucose-derived alanine.

Authors:  Renata Leke; Lasse K Bak; Malene Anker; Torun M Melø; Michael Sørensen; Susanne Keiding; Hendrik Vilstrup; Peter Ott; Luis V Portela; Ursula Sonnewald; Arne Schousboe; Helle S Waagepetersen
Journal:  Neurotox Res       Date:  2010-05-18       Impact factor: 3.911

Review 6.  Histological grading and staging of chronic hepatitis.

Authors:  K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween
Journal:  J Hepatol       Date:  1995-06       Impact factor: 25.083

7.  Changes in apparent systemic clearance of propofol during transplantation of living related donor liver.

Authors:  D Takizawa; E Sato; H Hiraoka; A Tomioka; K Yamamoto; R Horiuchi; F Goto
Journal:  Br J Anaesth       Date:  2005-09-16       Impact factor: 9.166

8.  Prevention of critical telomere shortening by oestradiol in human normal hepatic cultured cells and carbon tetrachloride induced rat liver fibrosis.

Authors:  R Sato; C Maesawa; K Fujisawa; K Wada; K Oikawa; Y Takikawa; K Suzuki; H Oikawa; K Ishikawa; T Masuda
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

9.  The significance of ammonia/gamma-aminobutyric acid (GABA) ratio for normality and liver disorders.

Authors:  Brett I Cohen
Journal:  Med Hypotheses       Date:  2002-12       Impact factor: 1.538

Review 10.  Gut ammonia production and its modulation.

Authors:  Manuel Romero-Gómez; María Jover; J Jorge Galán; A Ruiz
Journal:  Metab Brain Dis       Date:  2008-12-10       Impact factor: 3.584

View more
  3 in total

1.  Efficacy and Safety of Remimazolam Tosilate versus Propofol for General Anesthesia in Cirrhotic Patients Undergoing Endoscopic Variceal Ligation.

Authors:  Fu Shi; Yanjie Chen; Hongtao Li; Yang Zhang; Tonghang Zhao
Journal:  Int J Gen Med       Date:  2022-01-13

2.  Xylazine Regulates the Release of Glycine and Aspartic Acid in Rat Brain.

Authors:  Yi-Ming Zhang; Dong-Xu Yu; Bai-Shuang Yin; Xin-Ran Li; Li-Na Li; Ya-Nan Li; Yu-Xin Wang; Yu Chen; Wen-Han Liu; Li Gao
Journal:  J Vet Res       Date:  2018-03-30       Impact factor: 1.744

3.  Safety, pharmacokinetics and pharmacodynamics of a novel γ-aminobutyric acid (GABA) receptor potentiator, HSK3486, in Chinese patients with hepatic impairment.

Authors:  Yue Hu; Xiaojiao Li; Jingrui Liu; Hong Chen; Wenbo Zheng; Hong Zhang; Min Wu; Cuiyun Li; Xiaoxue Zhu; Jinfeng Lou; Pangke Yan; Nan Wu; Xiao Liu; Shiping Ma; Xu Wang; Yanhua Ding; Chengluan Xuan
Journal:  Ann Med       Date:  2022-12       Impact factor: 5.348

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.